Cantor Fitzgerald Reaffirms Overweight Rating for Septerna (NASDAQ:SEPN)

Septerna (NASDAQ:SEPN - Get Free Report)'s stock had its "overweight" rating reiterated by equities researchers at Cantor Fitzgerald in a note issued to investors on Tuesday,Benzinga reports. They presently have a $50.00 price objective on the stock. Cantor Fitzgerald's price objective would indicate a potential upside of 281.10% from the stock's current price.

A number of other research analysts have also issued reports on the stock. TD Cowen initiated coverage on shares of Septerna in a research note on Tuesday, November 19th. They set a "buy" rating on the stock. JPMorgan Chase & Co. initiated coverage on shares of Septerna in a research note on Tuesday, November 19th. They set an "overweight" rating and a $38.00 price target on the stock. Finally, Wells Fargo & Company initiated coverage on shares of Septerna in a report on Tuesday, November 19th. They set an "overweight" rating and a $43.00 price objective on the stock.

Septerna Stock Up 13.6 %

Shares of Septerna stock traded up $1.57 on Tuesday, reaching $13.12. 115,815 shares of the stock were exchanged, compared to its average volume of 235,876. Septerna has a 1-year low of $10.34 and a 1-year high of $28.99. The stock's fifty day simple moving average is $19.60.

Institutional Trading of Septerna

A number of institutional investors have recently added to or reduced their stakes in the stock. Avoro Capital Advisors LLC purchased a new stake in shares of Septerna in the fourth quarter valued at about $25,419,000. TRV GP V LLC purchased a new stake in shares of Septerna in the fourth quarter valued at about $142,337,000. TRV GP VI LLC purchased a new stake in shares of Septerna in the fourth quarter valued at about $72,191,000. Vanguard Group Inc. purchased a new stake in shares of Septerna in the fourth quarter valued at about $22,557,000. Finally, Corebridge Financial Inc. purchased a new stake in shares of Septerna in the fourth quarter valued at about $212,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.